WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed’s unique position as the world’s only supplier of... Read More

Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024. Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the... Read More

WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025". The corrected release follows: IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter... Read More

WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the... Read More

WINTER SPRINGS, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that it will participate in the 37 th Annual Roth Conference. Iradimed’s CFO, Jack Glenn, and CCO, Jeff Chiprin, will host one-on-one meetings between company management and investors at the 37th Annual Roth Conference, which will be held at the Laguna Cliffs Marriott in Dana Point, CA, on March 17 and... Read More

Reports record revenue of $19.4 million for the fourth quarter of 2024, an increase of $1.9 million or 11%, compared to the same period in 2023. Reports GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.44 for the fourth quarter of 2024. Reports GAAP diluted EPS of $1.50 and non-GAAP diluted EPS of $1.66 for the full year of 2024. Declares a regular quarterly cash dividend of $0.17 per common share for the first... Read More

WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in... Read More

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 million Iradimed is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025, at 5:15 p.m. PT WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the... Read More

WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43 rd Annual J.P. Morgan... Read More

WINTER SPRINGS, Fla., Dec. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), today announced it has been ranked 24 th on Forbes’ list of America’s Most Successful Small-Cap Companies 2025. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices... Read More

WINTER SPRINGS, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune’s 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems... Read More

Reports record revenue of $18.3 million for the third quarter of 2024, an increase of $1.8 million or 11% over the comparable period 2023. Reports GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024 Raising year end guidance on GAAP diluted earnings per share to $1.49 to $1.52 from $1.37 to $1.47, and Non-GAAP diluted earnings per share to $1.64 to $1.67 from $1.52 to $1.62. Declares a... Read More

WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 third quarter financial results before the market opens on Thursday, October 31, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the... Read More

WINTER SPRINGS, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference. Iradimed’s CFO, Jack Glenn, will host one-on-one meetings with investors at the 3rd Annual ROTH Healthcare Opportunities... Read More

WINTER SPRINGS, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that the Company will be participating in the Lake Street 8 th Annual Best Ideas Growth "Big 8" Conference . Iradimed management will host one-on-one meetings between company management and investors at the Lake... Read More

Reports record revenue of $17.9 million for the second quarter of 2024, an increase of 11.2 percent over the comparable period 2023. Reports GAAP diluted EPS of $0.38 and non-GAAP diluted EPS of $0.42 for the second quarter of 2024. Reports second quarter of 2024 operating income of $5.6 million, an increase of 13.4 percent compared to the comparable period of 2023. Declares a regular quarterly cash dividend of $0.15 per... Read More

Winter Springs, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 second quarter financial results before the market opens on Thursday, August 1, 2024. Iradimed management will host a conference call the same day beginning at 12:00 p.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the... Read More

WINTER SPRINGS, Fla., June 07, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today its common stock will uplist and commence trading on the Nasdaq Global Market, effective June 14, 2024, and will continue under the ticker symbol “IRMD.” Stockholders are not required to take any action due to... Read More

Reports record revenue of $17.6 million for the first quarter of 2024. Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024. Reports first quarter of 2024 operating income of $4.7 million, an increase of 18.5 percent compared to the same period in 2023. Declares a regular quarterly cash dividend of $0.15 per common share for the second quarter of 2024, payable May 30, 2024. WINTER... Read More

WINTER SPRINGS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 first quarter financial results before the market opens on Thursday, May 2, 2024. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the... Read More

WINTER SPRINGS, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, the Company's President and Chief Executive Officer, will present at the 36th Annual Roth Conference in Laguna Niguel, CA. Mr. Susi is scheduled for a live fireside chat on Tuesday, March 19, at 12:30 p.m. PT. A live webcast and a replay of the fireside chat will be available on... Read More

Reports record revenue of $17.5 million for the fourth quarter and $65.6 million for the full year of 2023. Reports GAAP diluted EPS of $0.36 and non-GAAP diluted EPS of $0.39 for the fourth quarter of 2023. Reports GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.48 for the full year of 2023. Reports fourth quarter of 2023 operating income of $5.2 million, an increase of 21.3%, compared to the same period in 2022... Read More

WINTER SPRINGS, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 fourth quarter financial results before the market opens on Thursday, February 8, 2024. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the... Read More

Reports preliminary fourth quarter 2023 revenue of $17.5 million WINTER SPRINGS, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (‘MRI”) compatible medical devices, today reported unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023. The fourth-quarter revenue totaled approximately $17.5... Read More

WINTER SPRINGS, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices, today announced that the Company will be participating in the upcoming 42 nd Annual J.P. Morgan Healthcare Conference. Iradimed’s CEO, Roger Susi, is scheduled to present on Thursday, January 11, 2024, at 12:00 p.m.... Read More

WINTER SPRINGS, Fla., Dec. 12, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD) announced today that its Board of Directors approved a special cash dividend of $0.48 per share and the initiation of a regular quarterly dividend on the Company's outstanding common stock. The regular quarterly dividend is $0.15 per share. The special cash dividend and the quarterly dividend are payable on January 12,... Read More

WINTER SPRING, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named on Forbes’ latest list of America’s Most Successful Small-Cap Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only... Read More

Reports record revenue of $16.5 million for the third quarter of 2023. GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.43. Third quarter operating income of $5.9 million, an increase of 43% compared to the same period in 2022. WINTER SPRINGS, Fla., Nov. 03, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September... Read More

WINTER SPRINGS, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 third quarter financial results before the market opens on Friday, November 3 rd . IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the... Read More

WINTER SPRINGS, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that the Company will be participating in two upcoming investor conferences. Iradimed management is scheduled to participate in investor meetings at the H.C. Wainwright 25 th Annual Global Investment Conference on Tuesday and Wednesday, September 12-13, 2023, at the Lotte New York Palace Hotel in New... Read More

Reports record revenue of $16.1 million for the second quarter of 2023 GAAP diluted EPS of $0.33 and non-GAAP diluted EPS of $0.36 Operating income was $5.0 million and increased by 19% Announces third quarter and full year 2023 financial guidance WINTER SPRINGS, Fla., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three and six months... Read More

WINTER SPRINGS, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 second quarter financial results before the market opens on Thursday, August 3 rd . Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the... Read More

WINTER SPRINGS, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), was recently named on Forbes’ latest list of America’s Best Small Companies for 2023. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider... Read More

Reports record revenue of $15.5 million for the first-quarter quarter of 2023 GAAP diluted EPS of $0.27 and non-GAAP diluted EPS of $0.30 Operating income was $4.0 million and increased by 30% Announces second quarter 2023 financial guidance and increases full-year 2023 financial guidance WINTER SPRINGS, Fla., May 04, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial... Read More

WINTER SPRINGS, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2023 first quarter financial results before the market opens on Thursday, May 4th. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the... Read More

WINTER SPRINGS, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that Roger Susi, President and Chief Executive Officer of the Company, will be presenting at the 35 th Annual Roth Conference in Laguna Niguel, CA. Mr. Susi is scheduled for a live fireside chat on Monday, March 13, at 11:30 am PT. A live webcast and a replay of the fireside chat will be available on... Read More

WINTER SPRINGS, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) issued an Urgent Medical Device Correction Letter to notify affected customers of a potential issue with some 1057 Syringe Adapter Sets related to the syringe venting function during use which can lead to reduced flow with the MRidium infusion pump resulting in subsequent inlet occlusion and alarm indication. The 1057... Read More

Reports fourth quarter 2022 revenue of $14.9 million, GAAP diluted EPS of $0.29 and non-GAAP diluted EPS of $0.32. Reports full-year 2022 revenue of $53.3 million, GAAP diluted EPS of $1.02 and non-GAAP diluted EPS of $1.10. The Board of Directors approved a special cash dividend of $1.05 per share. This special cash dividend is payable on February 21, 2023, to shareholders of record at the close of business on February 13,... Read More

WINTER SPRINGS, Fla., Jan. 26, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2022 fourth quarter financial results before the market opens on Thursday, February 2, 2023. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. IRADIMED has scheduled a conference call to... Read More

Reports preliminary fourth quarter 2022 revenue of $14.9 million Announces full-year and first-quarter 2023 financial guidance WINTER SPRINGS, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced selected preliminary financial results for the fourth quarter that ended December 31, 2022. Fourth-quarter revenue is expected to be approximately $14.9 million, up 25% from the... Read More